David Grayzel

David is a partner and focuses on investments in novel therapeutics, often those that are near to first in human clinical testing.

Since joining Atlas in 2010, David has co-founded and served as chief executive officer of numerous companies including Arteaus Therapeutics acquired by Eli Lilly in 2014, Annovation Biopharma acquired by The Medicines Company in 2015, and was a founding board member of both Delinia acquired by Celgene in 2017, and Cadent Therapeutics acquired by Novartis in 2020. David is a co-founder and board member of Surface Oncology (NASDAQ: SURF) and Q32 Bio. David also sits on the boards of Xilio Therapeutics, Affinia Therapeutics, and Aerovate Therapeutics, and is a board observer at Day One Biopharmaceuticals.

David serves as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the American Heart Association’s One Brave Idea, and is on the Scientific Advisory Board of the Tri-TDI that includes Rockefeller University, MSKCC, and Cornell. He earned his B.A. from Stanford University, an M.D. from Harvard Medical School, and completed his internship and residency training in internal medicine at Massachusetts General Hospital. He also serves on the board of Acera: The Massachusetts School for Science, Creativity, and Leadership, a STEM focused K-8 school, which his wife Courtney founded in 2009.